M. Kulyk & Associates LLC Sells 11,801 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

M. Kulyk & Associates LLC reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 11.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 88,666 shares of the biopharmaceutical company's stock after selling 11,801 shares during the quarter. Gilead Sciences accounts for 1.8% of M. Kulyk & Associates LLC's investment portfolio, making the stock its 17th biggest holding. M. Kulyk & Associates LLC's holdings in Gilead Sciences were worth $8,190,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the business. HHM Wealth Advisors LLC boosted its stake in shares of Gilead Sciences by 118.5% during the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 154 shares during the period. YANKCOM Partnership acquired a new stake in Gilead Sciences during the fourth quarter valued at $28,000. Decker Retirement Planning Inc. acquired a new position in Gilead Sciences in the 4th quarter worth about $29,000. Crews Bank & Trust purchased a new stake in shares of Gilead Sciences during the 4th quarter worth about $31,000. Finally, Stephens Consulting LLC grew its stake in shares of Gilead Sciences by 325.0% in the 4th quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 260 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Oppenheimer raised their price objective on shares of Gilead Sciences from $115.00 to $132.00 and gave the company an "outperform" rating in a research report on Tuesday, March 4th. BMO Capital Markets lifted their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research note on Wednesday, February 12th. Citigroup initiated coverage on shares of Gilead Sciences in a report on Thursday, November 14th. They issued a "buy" rating and a $125.00 price objective for the company. The Goldman Sachs Group raised their target price on Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a report on Wednesday, February 12th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Eleven investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $104.52.

Remove Ads

Gilead Sciences Price Performance

Shares of GILD stock traded down $2.69 during mid-day trading on Tuesday, reaching $114.52. The company's stock had a trading volume of 7,935,973 shares, compared to its average volume of 8,169,864. The firm's 50-day moving average is $100.12 and its two-hundred day moving average is $91.91. The company has a market cap of $142.62 billion, a P/E ratio of 309.52, a PEG ratio of 0.71 and a beta of 0.21. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be paid a $0.79 dividend. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 2.76%. Gilead Sciences's payout ratio is currently 854.05%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now directly owns 129,873 shares in the company, valued at $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 293,356 shares of company stock worth $29,166,240 over the last three months. Company insiders own 0.16% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.